0001140361-20-011444.txt : 20200512 0001140361-20-011444.hdr.sgml : 20200512 20200512164045 ACCESSION NUMBER: 0001140361-20-011444 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200512 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200512 DATE AS OF CHANGE: 20200512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSULET CORP CENTRAL INDEX KEY: 0001145197 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33462 FILM NUMBER: 20869648 BUSINESS ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-600-7000 MAIL ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 8-K 1 nt10011845x3_8k.htm FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 12, 2020

INSULET CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware
001-33462
04-3523891
(State or Other Jurisdiction of
Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)

100 Nagog Park,
Acton, Massachusetts 01720
(Address of Principal Executive Offices, including Zip Code)


Registrant’s telephone number, including area code: (978) 600-7000

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
☐
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
☐
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
☐
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.001 Par Value Per Share
  
PODD
  
The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec.230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Sec.240.12b-2 of this chapter)
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐


Item 7.01.          Regulation FD Disclosure.
On May 12, 2020, Insulet Corporation (the “Company”) announced that it plans to make an offering of $500 million of its common stock in a registered underwritten offering.

The Company also issued a press release on May 12, 2020 announcing the offering. A copy of the press release is attached hereto as Exhibit 99.1.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful. Any offers of the Company’s common stock will be made only by means of a prospectus and the related prospectus supplement.

The information contained in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances.

These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause or contribute to a material difference include, but are not limited to, the risks discussed in our other filings with the SEC and the following: risks associated with public health crises and pandemics, such as the COVID-19 global pandemic, including the duration of the outbreak, government actions and restrictive measures implemented in response, supply chain disruptions, delays in clinical trials, and other impacts to the business, or on the Company’s ability to execute business continuity plans; risks associated with our dependence on our principal product platform, the Omnipod Insulin Management System (the “Omnipod System”), and our ability to design, develop, manufacture and commercialize future products; our ability to reduce production costs and increase customer orders and manufacturing volumes; adverse changes in general economic conditions; the impact of healthcare reform laws; our ability to raise additional funds in the future on acceptable terms or at all; supply problems or price fluctuations with sole source or third-party suppliers on which we are dependent; the potential establishment of a competitive bid program for conventional insulin pumps; failure to retain key supplies and/or supplier pricing discounts and achieve satisfactory gross margins; international business risks, including regulatory, commercial and logistics risks associated with the Company selling its products in Europe in light of the uncertainty related to the separation of the United Kingdom from the European Union (“Brexit”); our inability to secure and retain adequate coverage or reimbursement from third-party payors for the Omnipod System or future products and potential adverse changes in reimbursement rates or policies relating to the Omnipod System or future products; failure to retain key payor partners and their members; adverse effects resulting from competition; technological change and product innovation adversely affecting our business; changes to or termination of our license to incorporate a blood glucose meter into the Omnipod System or our inability to enter into new license or other agreements with respect to the Omnipod System’s current or future features; challenges to the future development of our non-insulin drug delivery product line; our ability to protect our intellectual property and other proprietary rights; conflicts with the intellectual property of third parties, including claims that our current or future products infringe or misappropriate the proprietary rights of others; adverse regulatory or legal actions relating to the Omnipod System or future products; failure of our contract manufacturers or component suppliers to comply with the U.S. Food and Drug Administration’s (“FDA”) quality system regulations; potential adverse impacts resulting from a recall, or discovery of serious safety issues, of our products; the potential violation of the U.S. Foreign Corrupt Practices Act or any other federal, state or foreign anti-bribery/anti-corruption law or laws prohibiting “kickbacks” or protecting the confidentiality of health information or other protected personal information, or any challenge to or investigation into our practices under these laws; product liability and other lawsuits that may be brought against us, including stemming from off-label use of our products; breaches or failures of our products or information technology systems, including by cyberattack; reduced retention rates of our customer base; unfavorable results of clinical studies relating to the Omnipod System or future products, or the products of our competitors; future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable to the Omnipod System; the concentration of our manufacturing operations and storage of inventory in a limited number of locations; our ability to attract and retain personnel; our ability to scale our business to support revenue growth; fluctuations in quarterly results of operations; risks associated with potential future acquisitions or investments in new businesses; our ability to generate sufficient cash to service all of our indebtedness; the expansion of our distribution network; the volatility of the trading price of our Common Stock; risks related to future sales of our common stock or the conversion of any of our convertible senior notes; potential limitations on our ability to use our net operating loss carryforwards; and anti-takeover provisions in our organizational documents.
The risk factors discussed in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019 and in our Quarterly Report on Form 10-Q for the period ended March 31, 2020 could cause our results to differ materially from those expressed in forward-looking statements. In addition, there may be other risks and uncertainties that we are unable to identify or predict at this time or that we currently do not expect to have a material adverse effect on our business. All forward-looking statements set forth in this Current Report on Form 8-K are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequence to or effects on us or our business or operations. Forward-looking statements set forth in this Current Report on Form 8-K speak only as of the date hereof and we do not undertake any obligation to update forward-looking statements to reflect subsequent events or circumstances, changes in expectations or the occurrence of unanticipated events, except to the extent required by law.

Item 9.01.          Financial Statements and Exhibits.
(d) Exhibits.

Exhibit No.
 
Description
     
Press Release, dated May 12, 2020, announcing the offering


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned thereunto duly authorized.

May 12, 2020 
INSULET CORPORATION
     
 
By:  
/s/ Wayde McMillan
 
 
Wayde McMillan
 
 
Chief Financial Officer

EX-99.1 2 nt10011845x3_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

Insulet Corporation Announces Plans for Public Offering of Common Stock
May 12, 2020
ACTON, Mass. – May 12, 2020 – Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), a global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that it plans to make an offering of $500 million of its common stock in a registered underwritten offering. Insulet expects to grant the underwriters a 30-day option to purchase up to $75 million of additional shares.

Insulet expects to use the net proceeds from the sale of the shares of its common stock in this offering for general corporate purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful. Any offers of the Company’s common stock will be made only by means of a prospectus and the related prospectus supplement, copies of which may be obtained, if and when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing at prospectus-eq_fi@jpmchase.com.

Morgan Stanley and J.P. Morgan are the joint book-running managers for the contemplated offering.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances.
These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause or contribute to a material difference include, but are not limited to, the risks discussed in our filings with the SEC and the following:  risks associated with public health crises and pandemics, such as the COVID-19 global pandemic, including the duration of the outbreak, government actions and restrictive measures implemented in response, supply chain disruptions, delays in clinical trials, and other impacts to the business, or on the Company’s ability to execute business continuity plans; risks associated with our dependence on our principal product platform, the Omnipod Insulin Management System (the “Omnipod System”), and our ability to design, develop, manufacture and commercialize future products; our ability to reduce production costs and increase customer orders and manufacturing volumes; adverse changes in general economic conditions; the impact of healthcare reform laws; our ability to raise additional funds in the future on acceptable terms or at all; supply problems or price fluctuations with sole source or third-party suppliers on which we are dependent; the potential establishment of a competitive bid program for conventional insulin pumps; failure to retain key supplies and/or supplier pricing discounts and achieve satisfactory gross margins; international business risks, including regulatory, commercial and logistics risks associated with the Company selling its products in Europe in light of the uncertainty related to the separation of the United Kingdom from the European Union (“Brexit”); our inability to secure and retain adequate coverage or reimbursement from third-party payors for the Omnipod System or future products and potential adverse changes in reimbursement rates or policies relating to the Omnipod System or future products; failure to retain key payor partners and their members; adverse effects resulting from competition; technological change and product innovation adversely affecting our business; changes to or termination of our license to incorporate a blood glucose meter into the Omnipod System or our inability to enter into new license or other agreements with respect to the Omnipod System’s current or future features; challenges to the future development of our non-insulin drug delivery product line; our ability to protect our intellectual property and other proprietary rights; conflicts with the intellectual property of third parties, including claims that our current or future products infringe or misappropriate the proprietary rights of others; adverse regulatory or legal actions relating to the Omnipod System or future products; failure of our contract manufacturers or component suppliers to comply with the U.S. Food and Drug Administration’s (“FDA”) quality system regulations; potential adverse impacts resulting from a recall, or discovery of serious safety issues, of our products; the potential violation of the U.S. Foreign Corrupt Practices Act or any other federal, state or foreign anti-bribery/anti-corruption law or laws prohibiting “kickbacks” or protecting the confidentiality of health information or other protected personal information, or any challenge to or investigation into our practices under these laws; product liability and other lawsuits that may be brought against us, including stemming from off-label use of our products; breaches or failures of our products or information technology systems, including by cyberattack; reduced retention rates of our customer base; unfavorable results of clinical studies relating to the Omnipod System or future products, or the products of our competitors; future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable to the Omnipod System; the concentration of our manufacturing operations and storage of inventory in a limited number of locations; our ability to attract and retain personnel; our ability to scale our business to support revenue growth; fluctuations in quarterly results of operations; risks associated with potential future acquisitions or investments in new businesses; our ability to generate sufficient cash to service all of our indebtedness; the expansion of our distribution network; the volatility of the trading price of our Common Stock; risks related to future sales of our common stock or the conversion of any of our convertible senior notes; potential limitations on our ability to use our net operating loss carryforwards; and anti-takeover provisions in our organizational documents.
The risk factors discussed in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019 and in our Quarterly Report on Form 10-Q for the period ended March 31, 2020 could cause our results to differ materially from those expressed in forward-looking statements. In addition, there may be other risks and uncertainties that we are unable to identify or predict at this time or that we currently do not expect to have a material adverse effect on our business. All forward-looking statements set forth in this press release are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequence to or effects on us or our business or operations. Forward-looking statements set forth in this press release speak only as of the date hereof and we do not undertake any obligation to update forward-looking statements to reflect subsequent events or circumstances, changes in expectations or the occurrence of unanticipated events, except to the extent required by law.
Investor Relations Contact:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Media Contact:

Angela Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
 EX-101.SCH 3 podd-20200512.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 podd-20200512_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company EX-101.PRE 5 podd-20200512_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 nt10011875x3_img01.jpg begin 644 nt10011875x3_img01.jpg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xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-20-011444-xbrl.zip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end EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 nt10011845x3_8k_htm.xml IDEA: XBRL DOCUMENT 0001145197 2020-05-12 2020-05-12 false 0001145197 8-K 2020-05-12 INSULET CORPORATION DE 001-33462 04-3523891 100 Nagog Park Acton MA 01720 978 600-7000 false false false false Common Stock, $0.001 Par Value Per Share PODD NASDAQ false XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://insulet.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports nt10011845x3_8k.htm nt10011845x3_ex99-1.htm podd-20200512.xsd podd-20200512_lab.xml podd-20200512_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false XML 13 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
May 12, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 12, 2020
Entity Registrant Name INSULET CORPORATION
Entity Incorporation, State or Country Code DE
Entity File Number 001-33462
Entity Tax Identification Number 04-3523891
Entity Address, Address Line One 100 Nagog Park
Entity Address, City or Town Acton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01720
City Area Code 978
Local Phone Number 600-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001145197
Title of 12(b) Security Common Stock, $0.001 Par Value Per Share
Trading Symbol PODD
Security Exchange Name NASDAQ

XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nt10011845x3_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "nt10011845x3_8k.htm" ] }, "labelLink": { "local": [ "podd-20200512_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "podd-20200512_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "podd-20200512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "podd", "nsuri": "http://insulet.com/20200512", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nt10011845x3_8k.htm", "contextRef": "c20200512to20200512", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://insulet.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nt10011845x3_8k.htm", "contextRef": "c20200512to20200512", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insulet.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" }